tirzepatide (Mounjaro, Zepbound)

From Aaushi
Jump to navigation Jump to search

Indications

* weight reductions at 15 mg week approach those of bariatric surgery[8]

Contraindications

Dosage

* if 1 or 2 consecutive doses are missed, resume at last administered dose

* if >= 3 consecutive doses are missed, restart dose escalation starting at 5 mg

Adverse effects

Drug interactions

Mechanism of action

Clinical trials

Notes

More general terms

References

  1. 1.0 1.1 Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet 2021 Jun 25; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34186022 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext
    Frias JP, Davies MJ, Rosenstock J et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021 Jun 25; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34170647 https://www.nejm.org/doi/10.1056/NEJMoa2107519
  2. 2.0 2.1 Dahl D, Onishi Y, Norwood P et al Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35133415 https://jamanetwork.com/journals/jama/fullarticle/2788781
  3. 3.0 3.1 Zoler ML 'Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabetes. Medscape. May 13, 2022 https://www.medscape.com/viewarticle/974013
  4. 4.0 4.1 4.2 Zoler ML Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial. Medcape. June 4, 2022 https://www.medscape.com/viewarticle/975061
    Monaco K Tirzepatide Serves Up Major Weight-Loss Win in Patients With Obesity. SURMOUNT-1 trial tested GIP/GLP-1 receptor agonist in people without diabetes. MedPage Today June 5, 2022 https://www.medpagetoday.com/meetingcoverage/ada/99060
    McCall B 'Staggering' Weight Loss and Benefits in Body Composition With Tirzepatide. Medscape. May 19, 2023 https://www.medscape.com/viewarticle/992211
  5. 5.0 5.1 Busko M Tirzepatide Lowers Weight Across All Groups With Obesity. Medscape. November 07, 2022 https://www.medscape.com/viewarticle/983672
  6. 6.0 6.1 Zoler ML Tirzepatide's Benefits Expand: Lean Mass Up, Serum Lipids Down. Medscape. Oct 14, 2022 https://www.medscape.com/viewarticle/982467
  7. 7.0 7.1 NEJM Knowledge+ Endocrinology
  8. 8.0 8.1 8.2 Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022 Jul 21; 387:205. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35658024 https://www.nejm.org/doi/10.1056/NEJMoa2206038
    Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023 Jun 26; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37385275 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
  9. 9.0 9.1 Scherer L Caution Urged for Obesity Drugs and Birth Control Pills. Medscape. Oct 19, 2023 https://www.medscape.com/s/viewarticle/997498
  10. Abbasi J FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management JAMA. Published online November 15, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37966831
  11. 11.0 11.1 11.2 Aronne LJ, Sattar N, Horn DB et al Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. The SURMOUNT-4 Randomized Clinical Trial. JAMA. Published online December 11, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38078870 https://jamanetwork.com/journals/jama/fullarticle/2812936
  12. Tchang B How to Prescribe Zepbound. Medscape. Dec 12, 2023 https://www.medscape.com/viewarticle/999162
  13. 13.0 13.1 de Lemos JA, Linetzky B, le Roux CW et al Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >= 27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 2024 Feb 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38314555
  14. 14.0 14.1 Yao H et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis. BMJ 2024 Jan 29; 384:e076410. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38286487 PMCID: PMC10823535 Free PMC article https://www.bmj.com/content/384/bmj-2023-076410
  15. Highlights of Prescribing Information Mounjaro (tirzepatide) injection for subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf